about
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.Classifying early-onset colorectal cancer according to tumor location: new potential subcategories to exploreAnthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agentsLauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain.Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
P50
Q33427367-5C3C2F88-C659-41D7-95EF-0EC30CFE1567Q35786931-9122B826-8CD4-4F98-A9D2-7A15CEFA2FFBQ35993186-193E7EE9-47A5-4095-BAEE-8D55791E847AQ36341670-8B757F84-8B6A-468B-92DD-61FCCEE2CB61Q36343047-30B363BA-9979-4B52-B29D-AFAC5945BC43Q38647893-9595F7B8-1B10-4B5F-B546-9E338E8AECDEQ40592991-1EF8B415-57A0-480A-9C74-F5591AFF1BB4Q47307860-4803DB08-C32D-4A3C-82D7-1B1DD698F4F2Q47323830-9B0E9D45-4746-4341-91E3-66CAA50964DEQ47960062-984EDEDD-BE42-4817-902B-605D849B6BD7Q50556411-95CF8934-2B8D-43B0-ADAF-4804BB7D6C98Q52369488-0D796DBE-DA2A-4264-9346-48FBC435130BQ52597605-A601BB34-1C03-4A05-B8F1-4280D5F8416DQ53108051-74363314-F4F4-462C-82F1-DAD8A604920BQ57705524-A04C3D5C-6DD6-4F9C-84BE-0E810D9EB1C9
P50
description
researcher ORCID id 0000-0002-2493-0988
@en
wetenschapper
@nl
name
Juana María Cano
@ast
Juana María Cano
@en
Juana María Cano
@es
Juana María Cano
@nl
type
label
Juana María Cano
@ast
Juana María Cano
@en
Juana María Cano
@es
Juana María Cano
@nl
prefLabel
Juana María Cano
@ast
Juana María Cano
@en
Juana María Cano
@es
Juana María Cano
@nl
P106
P21
P31
P496
0000-0002-2493-0988